Omeros Participates in Investor Conference Focused on COVID-19 Therapeutics in Development
Omeros Participates in Investor Conference Focused on COVID-19 Therapeutics in Development
Omeros Corporation (Nasdaq: OMER) announced that results from its compassionate use study evaluating narsoplimab in COVID-19 patients in Italy will be shared during a virtual event being hosted today for registered participants only by ROTH Capital Partners entitled COVID-19 Therapeutics in Development: Beyond Gilead, Regeneron and Lilly. The presentation, which is part of a session on immune modulators to ameliorate COVID-19, is being made by Gregory A. Demopulos, M.D., Omeros’ chairman and chief executive officer. Dr. Demopulos’ slide presentation from the conference session can be viewed at https://investor.omeros.com/presentations.
Omeros previously announced positive results from the treatment with narsoplimab of six critically ill COVID-19 patients under a compassionate use protocol in Bergamo, Italy. All patients initially required mechanical ventilation and, following treatment with narsoplimab, all recovered, survived and were discharged from the hospital. Five to six months following discharge, none of the patients showed any clinical or laboratory evidence of longer-term effects from COVID-19. Additional compassionate use with narsoplimab is ongoing in Bergamo.